Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer
… with non–small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative
example of the successes in targeting oncogene addiction in cancer and the role of tumor-…
example of the successes in targeting oncogene addiction in cancer and the role of tumor-…
[HTML][HTML] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer …
ACZ Gelatti, A Drilon, FC Santini - Lung cancer, 2019 - Elsevier
… Lung cancer is the leading cause of cancer-related mortality globally, … lung cancer (NSCLC)
is the most common type of lung cancer, accounting for approximately 80–90% of all lung …
is the most common type of lung cancer, accounting for approximately 80–90% of all lung …
Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview
D Das, J Wang, J Hong - ChemMedChem, 2021 - Wiley Online Library
… New discoveries of potent kinase inhibitors and … kinase inhibitors against NSCLC, along
with medicinal chemistry aspects and related developments in next-generation kinase inhibitors …
with medicinal chemistry aspects and related developments in next-generation kinase inhibitors …
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
M Offin, H Rizvi, M Tenet, A Ni, F Sanchez-Vega… - Clinical Cancer …, 2019 - AACR
… checkpoint blockade in patients with lung cancer, but the impact of … lung cancers, we found
an inverse relationship between TMB and clinical benefit of EGFR-tyrosine kinase inhibitors (…
an inverse relationship between TMB and clinical benefit of EGFR-tyrosine kinase inhibitors (…
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
E Santoni-Rugiu, LC Melchior, EM Urbanska… - Cancers, 2019 - mdpi.com
… receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) can function as
oncogenic driver and target for precision medicine intervention in lung cancer cells [1]. Once …
oncogenic driver and target for precision medicine intervention in lung cancer cells [1]. Once …
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
KN Shah, R Bhatt, J Rotow, J Rohrberg, V Olivas… - Nature medicine, 2019 - nature.com
… We sought to determine the relevant target of Aurora kinase inhibitors in driving drug
synergy. We found approximately twofold messenger RNA upregulation but no increase in total …
synergy. We found approximately twofold messenger RNA upregulation but no increase in total …
[HTML][HTML] Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
… in RET fusion-positive lung cancer treated with RET tyrosine kinase inhibitors (TKIs). …
Importantly, lung cancers harboring RET fusions are sensitive to tyrosine kinase inhibitors (TKIs) …
Importantly, lung cancers harboring RET fusions are sensitive to tyrosine kinase inhibitors (TKIs) …
MEK inhibitors for the treatment of non-small cell lung cancer
J Han, Y Liu, S Yang, X Wu, H Li, Q Wang - Journal of Hematology & …, 2021 - Springer
… inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor
receptor-tyrosine kinase inhibitors or BRAF inhibitors … other drugs with MEK inhibitors to …
receptor-tyrosine kinase inhibitors or BRAF inhibitors … other drugs with MEK inhibitors to …
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer
XS Wang, YF Bai, V Verma, RL Yu… - … the National Cancer …, 2023 - academic.oup.com
… The management of metastatic non-small cell lung cancer (NSCLC) with a limited number …
standard of care for metastatic EGFRm NSCLC is tyrosine kinase inhibitor (TKI) therapy (4,5). …
standard of care for metastatic EGFRm NSCLC is tyrosine kinase inhibitor (TKI) therapy (4,5). …
Emerging therapies for non-small cell lung cancer
… kinase inhibitors and immunotherapy for lung cancer are the … including tyrosine kinase
inhibitors, checkpoint inhibitors, and … for non-small cell lung cancer attempting to provide insights …
inhibitors, checkpoint inhibitors, and … for non-small cell lung cancer attempting to provide insights …
相关搜索
- cell lung cancer kinase inhibitors
- cell lung cancer kinase targeted therapies
- non-small cell lung cancer
- egfr tyrosine kinase inhibitors
- growth factor receptor tyrosine kinase inhibitors
- lung cancer ret fusion
- lung cancer mechanisms of resistance
- cell lung cancer acquired resistance
- small cell lung cancer egfr tki
- cell lung cancer first line treatment
- egfr mutant lung cancers kinase inhibitors
- lung cancer egfr inhibitors
- cell lung cancer mek inhibitors
- cell lung cancer patients
- receptor tyrosine kinase inhibitors lung cancers